Search

Displaying results 2311 - 2320 of 10000 in total
  1. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]

  2. Drug

    Mephenytoin

    go.drugbank.com/drugs/DB00532
    ApprovedWithdrawn

    These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.

  3. Drug

    Conjugated estrogens

    go.drugbank.com/drugs/DB00286
    ApprovedInvestigational

    It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine. … The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material.

  4. Drug

    Macimorelin

    go.drugbank.com/drugs/DB13074
    Approved

    Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. … In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function [A31484].

  5. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.

  6. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation.

  7. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]

  8. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

  9. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative ...

  10. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.

    International brands: Kalymin N